Dendreon's Phase 1 Results Of APC8024--anti-Her-2--Therapeutic Vaccine Demonstrate Ongoing Clinical Benefit in Women with Advanced, Metastatic Breast Cancer.
Linked as:
Extract
Dendreon's Phase 1 Results Of APC8024--anti-Her-2--Therapeutic Vaccine Demonstrate Ongoing Clinical Benefit in Women with Advanced, Metastatic Breast Cancer.
Environment Writers
BIOWIRE2K CHICAGO--(BUSINESS WIRE)--June 1, 2003 Long-term follow-up data presented at ASCO show meaningful clinical benefit Dendreon Corporation (NASDAQ:DNDN) today announced that results from its ongoing Phase 1 trial of APC8024, the company's investigational therapeutic vaccine for breast, col...See the full content of this document
Sponsored links
